What's The Future of Cancer Immunotherapy? World Renowned Cancer Expert Shares His Perspective

curncman
Posts: 1160
Joined: Fri Jun 26, 2020 8:27 am

Re: What's The Future of Cancer Immunotherapy? World Renowned Cancer Expert Shares His Perspective

Post by curncman »

Bone marrow-derived stem cells to treat stroke, MS and chronic TBI


trader32176
Posts: 3709
Joined: Fri Jun 26, 2020 5:22 am

Re: What's The Future of Cancer Immunotherapy? World Renowned Cancer Expert Shares His Perspective

Post by trader32176 »

The Effect of Stroke on Bone Marrow: Studies from a Cell-Therapy Clinical Trial

https://www.ahajournals.org/doi/abs/10. ... pl_1.a3116

Abstract


Objective: The application of autologous bone marrow cells has emerged as an investigational cell-based therapy for ischemic stroke. Previous animal studies have reported that stroke affects leukocytes in the bone marrow. In addition, older age and presence of comorbidities raise concerns about the variability in yield of bone marrow stem cells. These issues may potentially impact autologous applications of bone marrow cell therapies in stroke patients. We examined whether acute ischemic stroke (AIS) affects the bone marrow in patients by assessing various cell subpopulations within the mononuclear fraction of bone marrow harvested from healthy donors and study patients in our clinical trial testing mononuclear cells (MNCs) in patients with AIS.

Methods:
This study examined the bone marrow composition of 22 consecutive patients with AIS enrolled into our clinical trial testing the safety of autologous bone marrow MNCs administered intravenously within 24 to 72 hours after symptom onset. After bone marrow harvest, MNCs are isolated, separated, and characterized at a GMP facility. The bone marrow from 15 healthy donors was also processed at the same GMP facility. Descriptive analysis comprised calculation of means for absolute cell counts and determination of proportions for subtypes of different cell subpopulations. Samples of healthy bone marrow donors were compared with that of AIS patients.

Results:
AIS patients had a median age of 61 (IQR 50-73), had CAD (5%), Afib (14%), diabetes (32%), hypertension (50%), hyperlipidemia (32%), or were actively smoking (27%). Onset time to harvest was 48 ±11 hours after stroke onset. Figure 1 shows no significant differences among the proportions of cell populations including lineage negative, CD34+ cells (a marker of hematopoietic stem cells - HSCs). There was no significant difference in the variance of the cell subpopulations between healthy donors and stroke patients, except for NK cells which were significantly higher among the stroke patients (p = 0.0074). Age, history of DM, or the location of the infarct depending on vascular territory did not affect the proportion of the different cell populations.

Conclusions:
AIS does not cause significant changes in the proportions of different cell types in the MNCs of bone marrow including the HSCs. We found no evidence that autologous MNCs are different, in terms of cell composition, from study patients who are older and have vascular comorbidities compared with healthy donors.

Originally published7 May 2018Stroke. 2012;43:A3116
curncman
Posts: 1160
Joined: Fri Jun 26, 2020 8:27 am

Herbal medicine that cures 84 chronic bronchitis and dissolves cancer cells

Post by curncman »

Herbal medicine that cures 84 chronic bronchitis and dissolves cancer cells

curncman
Posts: 1160
Joined: Fri Jun 26, 2020 8:27 am

Expanded 2021 Incyte Ingenuity Award Program

Post by curncman »

Expanded 2021 Incyte Ingenuity Award Program

Dr. Navneet Majhail, M.D., M.S., Director, Blood and Marrow Transplant Program, Cleveland Clinic, and an Incyte Ingenuity Award judge discusses the Incyte Ingenuity Award Program which was created to support people impacted by graft-versus-host disease (GVHD). This condition can occur after an allogeneic stem cell transplant where the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. The 2021 Incyte Ingenuity Award program has been expanded to now include a second $35,000 award in addition to the original $100,000 award to better support projects of different scales. Open for entries until June 30, 2021.

curncman
Posts: 1160
Joined: Fri Jun 26, 2020 8:27 am

X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia: Novel Treatment Options

Post by curncman »

X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia: Novel Treatment Options

curncman
Posts: 1160
Joined: Fri Jun 26, 2020 8:27 am

Autism treatment with stem cells | Stem Cell Therapy for Autism | Stem Cells for Autism Treatment

Post by curncman »

Autism treatment with stem cells | Stem Cell Therapy for Autism | Stem Cells for Autism Treatment

curncman
Posts: 1160
Joined: Fri Jun 26, 2020 8:27 am

Next-generation CAR T-cell therapies for advanced mesothelioma

Post by curncman »

Next-generation CAR T-cell therapies for advanced mesothelioma


curncman
Posts: 1160
Joined: Fri Jun 26, 2020 8:27 am

Fate Therapeutics' FT536 and FT819 Brief Overview

Post by curncman »

Fate Therapeutics' FT536 and FT819 Brief Overview


curncman
Posts: 1160
Joined: Fri Jun 26, 2020 8:27 am

Let's Talk Death with Dr. Santosh Kesari

Post by curncman »

Let's Talk Death with Dr. Santosh Kesari





Dr. Kesari has had a long-standing interest in cancer stem cells and studies their role in the formation of brain tumors and resistance to treatment. He believes that in order to cure patients with brain tumors we first need to gain a better molecular and biological understanding of the disease.

A physician/scientist, Kesari harnesses his experience in surgery, chemotherapy, immunotherapy, radiation therapy and novel devices to help develop Precision Therapeutic Strategies that will advance medicine to a new stage in the battle against brain tumors and eradicate the disease.
curncman
Posts: 1160
Joined: Fri Jun 26, 2020 8:27 am

Stem Cells and Multiple Sclerosis

Post by curncman »

Stem Cells and Multiple Sclerosis


Post Reply